Merck (MRK) said Tuesday it has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral lipoprotein(a) inhibitor in phase 2 trials in China for cardiovascular disease.
Under the deal, Merck will have global rights to develop, manufacture, and commercialize HRS-5346, excluding the Greater China region, with Hengrui receiving a $200 million upfront payment, potential milestone payments up to $1.77 billion, and royalties on sales, the companies said.
The transaction, subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other conditions, is expected to close in Q2, Merck added.
Merck expects to record a pre-tax charge of $200 million, or $0.06 per share, in the quarter the deal closes, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。